P/E ratio for Regeneron Pharmaceuticals (REGN)
P/E ratio as of May 2024 (TTM): 25.9
According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.9095. At the end of 2022 the company had a P/E ratio of 17.8.
P/E ratio history for Regeneron Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 17.8 | 115.55% |
| 2021 | 8.26 | -43.98% |
| 2020 | 14.7 | -23.92% |
| 2019 | 19.4 | 17.5% |
| 2018 | 16.5 | -50.5% |
| 2017 | 33.3 | -22.28% |
| 2016 | 42.9 | -51.34% |
| 2015 | 88.1 | -23.31% |
| 2014 | 115 | 80.78% |
| 2013 | 63.6 | 192.43% |
| 2012 | 21.7 | -195.69% |
| 2011 | -22.7 | -12.12% |
| 2010 | -25.9 | -9.13% |
| 2009 | -28.4 | 56.49% |
| 2008 | -18.2 | 20.44% |
| 2007 | -15.1 | 33.11% |
| 2006 | -11.3 | 21.23% |
| 2005 | -9.35 | -177.18% |
| 2004 | 12.1 | -276.3% |
| 2003 | -6.87 | 5.09% |
| 2002 | -6.54 | -57.96% |
| 2001 | -15.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 11.0 | -57.72% | 🇺🇸 USA |
 Novartis NVS | 27.5 | 5.97% | 🇨🇭 Switzerland |
 Amgen AMGN | 22.2 | -14.16% | 🇺🇸 USA |
 Sanofi SNY | 15.4 | -40.75% | 🇫🇷 France |
 Biogen BIIB | 12.5 | -51.90% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -36.8 | -242.01% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.